The tennis star said she's proof that you can do everything right and still struggle to lose weight
Chief Medical Officer, Kailera Therapeutics: Oral ribupatide shows a potentially game-changing clinical profile Kailera Therapeutics plans to initiate another Phase 2 oral study this year Chief of Clinical Development, Metabolic Diseases, Hengrui Pharma confirmed plans to advance into Phase 3 in China 5 Oral + injectable = portfolio hedge Kaileras lead injectable ribupatide (KAI-9531) already showed: 19.2% mean weight loss at 36 weeks (Phase 3, China) Comparable to @Eli Lilly and Companys Zepbound Oral ribupatide now adds access, convenience, and lifecycle flexibility
Cigna : Select Cigna plans cover this medication, especially when linked to obesity and related conditions
More Than a Number on the Scale Tirzepatides benefits go far beyond appearance
Nasal administration offers an easy, non-invasive option for consistent use, making it ideal for active individuals focused on recovery, resilience, and performance